Myriad Genetics CTO awarded 23,697 shares

Myriad Genetics Chief Technology Officer Kevin Richard Haas reported an acquisition of 23,697 shares of common stock of the company on February 2, 2026 at a price of $0 per share.

Rhea-AI Filing Summary

Myriad Genetics Chief Technology Officer Kevin Richard Haas reported an acquisition of 23,697 shares of common stock of the company on February 2, 2026 at a price of $0 per share. These shares relate to performance-based restricted stock units (PSUs) that were initially granted on March 15, 2023, with the final award amount determined by the board’s Compensation and Human Capital Committee based on preset performance metrics.

Each PSU represents a right to receive one share of Myriad Genetics common stock and is scheduled to vest on March 15, 2026. After this award, Haas beneficially owns 202,332 shares of Myriad Genetics common stock held directly.

Insider Trade Summary

Grant/Award: 23,697 shares

Grant/Award 1 txn

Insider Haas Kevin Richard

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	23,697	$0.00	$0.00

Holdings After Transaction: Common Stock — 202,332 shares (Direct)

Footnotes (1)

1. F1. Consists of performance-based restricted stock units (PSUs) initially granted on March 15, 2023, subject to accomplishment of pre-determined performance metrics. On February 2, 2026, the Compensation and Human Capital Committee of the Company's Board of Directors determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock and vests on March 15, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MYGN Chief Technology Officer Kevin Haas report?

Kevin Haas reported acquiring 23,697 shares of Myriad Genetics common stock at $0 per share. The acquisition stems from performance-based restricted stock units tied to preset performance metrics from a March 15, 2023 grant.

How many MYGN shares does Kevin Haas own after this Form 4 transaction?

After the reported transaction, Kevin Haas beneficially owns 202,332 shares of Myriad Genetics common stock. These shares are reported as directly held following the February 2, 2026 performance-based stock award.

What are the terms of Kevin Haas’s performance-based stock units at Myriad Genetics (MYGN)?

The performance-based restricted stock units were initially granted on March 15, 2023 and are tied to predetermined performance metrics. Each PSU converts into one share of common stock and is scheduled to vest on March 15, 2026.

When did Myriad Genetics (MYGN) determine the final award amount for Kevin Haas’s PSUs?

On February 2, 2026, the Compensation and Human Capital Committee of Myriad Genetics’ board determined the final PSU award amount for Kevin Haas, based on the accomplishment of the applicable performance metrics from the March 15, 2023 grant.

What role does performance play in Kevin Haas’s Myriad Genetics stock award?

The award consists of performance-based restricted stock units that depend on achieving pre-determined performance metrics. Only after these metrics were evaluated on February 2, 2026 was the final award of 23,697 shares confirmed for Kevin Haas.

When will Kevin Haas’s performance-based restricted stock units in MYGN vest?

Each performance-based restricted stock unit granted to Kevin Haas is scheduled to vest on March 15, 2026. At vesting, each PSU entitles him to receive one share of Myriad Genetics common stock, assuming the performance conditions were satisfied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 05:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Haas Kevin Richard

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A		23,697(1)	A	$0	202,332	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of performance-based restricted stock units (PSUs) initially granted on March 15, 2023, subject to accomplishment of pre-determined performance metrics. On February 2, 2026, the Compensation and Human Capital Committee of the Company's Board of Directors determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock and vests on March 15, 2026.

Remarks:

	By: Justin Hunter For: Kevin Richard Haas	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.